| Market Cap | $1.37B-13.7% |
| Revenue (ttm) | $20.00M |
| Net Income | -$150.47M |
| EPS | -$3.17 |
| Shares Out | 59.28M |
| PE Ratio | n/a |
| Forward PE | -5.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 437,720 |
| Open | $23.23 |
| Previous Close | $23.59 |
| Day's Range | $23.00 - $23.83 |
| 52-Week Range | $22.06 - $52.93 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | $64.21(+177.26%) |
| Earnings Date | Nov 4, 2026 |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Rapport Therapeutics, Inc. Stock Analysis — InsiderScore
Rapport Therapeutics, Inc. scored higher than 50% of companies evaluated by InsiderBuying, and ranked 42nd out of 107 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Rapport Therapeutics, Inc. bought $22.02 million of stock across 11 purchases in the last 90 days, the largest of them $20.00 million.
The average purchase added about 46% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
3 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating RAPP in the last 3 months, one vote each. Issuer-paid research is not counted.
$RAPP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RAPP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RAPP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RAPP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RAPP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RAPP from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from RAPP’s recent data — informational, not investment advice
What’s Behind the Score
News check: Only one headline directly addresses RAPP, suggesting valuation concerns despite recent decline; limited concrete news to establish clear bullish or bearish sentiment.
Recent Insider Activity
Insider Score Trend Over Time
+67.8 since Sep 4Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| IBRN | iShares Neuroscience and Healthcare ETF | 1.11% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.09% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.81% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.52% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.40% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.24% |
| MNTL | Tema Neuroscience And Mental Health ETF | 0.21% |
| IWC | iShares Micro-Cap ETF | 0.20% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.16% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.16% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.15% |
| FSCC | Federated Hermes MDT Small Cap Core ETF | 0.12% |
Weight is the stock’s share of each fund’s holdings.
